Welcome to our dedicated page for Scisparc SEC filings (Ticker: SPRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SciSparc Ltd. (Nasdaq: SPRC) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer. SciSparc files annual reports on Form 20-F and frequent current reports on Form 6-K, which together describe its clinical-stage pharmaceutical activities, capital structure, and material corporate events.
Recent Form 6-K filings highlight several categories of information. Transaction-related 6-Ks describe agreements such as the asset and share purchase arrangement through which SciSparc obtained a controlling interest in NeuroThera Labs Inc. and transferred its advanced clinical-stage pharmaceutical portfolio and its stake in SciSparc Nutraceuticals Inc. to NeuroThera. Other 6-Ks detail the sale of MitoCareX Bio Ltd. to N2OFF, Inc., the binding term sheet and definitive agreement to acquire a treasury of patents and trademarks for the MUSE endoscopic system from Xylo Technologies Ltd., and a framework agreement terminating a prior merger agreement with AutoMax Motors Ltd. and setting loan repayment terms.
Filings also cover capital markets and compliance matters, including inducement letter agreements with holders of existing warrants, under which warrant exercise prices were adjusted and SciSparc expects to receive gross proceeds for working capital and general corporate purposes. Another 6-K reports a Nasdaq notification that the company no longer met the minimum stockholders’ equity requirement for continued listing, and outlines the timeframe to submit a compliance plan.
In addition, SciSparc uses Form 6-K to furnish financial statements and MD&A, such as unaudited consolidated interim financial statements and management’s discussion and analysis for the six months ended June 30, 2025. Patent- and R&D-related press releases—covering NeuroThera’s opioid–N-acylethanolamine patent, MEAI-based depression patent applications, and the quantum computing-enabled 3D protein modeling initiative—are also incorporated by reference via 6-K exhibits.
On this page, users can review SciSparc’s 6-K submissions, including exhibits like binding term sheets, asset and share purchase agreements, and inducement letters, alongside its 20-F annual report. AI-powered tools summarize key points from these filings, highlight items such as equity transactions, IP acquisitions, and listing status updates, and help readers navigate complex transaction terms and risk disclosures without reading every page in detail.
SciSparc Ltd. reported that its majority-owned subsidiary, NeuroThera Labs Inc., has been granted a U.S. patent covering proprietary combinations of antimicrobials and cannabinoids aimed at overcoming antimicrobial resistance, including Methicillin-resistant Staphylococcus aureus (MRSA). The patent protects compositions and methods designed to enhance the effectiveness of existing antibiotics against resistant bacterial strains.
NeuroThera’s platform combines established antibiotics with cannabinoids such as THC, CBD and, in some embodiments, PEA. Pre-clinical studies showed enhanced antimicrobial activity, potentially restoring efficacy against resistant Gram‑positive pathogens like MRSA while leveraging long-term safety data of well-known antibiotics.
The company highlights the growing global burden of antimicrobial resistance, noting millions of deaths associated with resistant infections, and cites projections that the global antibiotics market may reach about $58 billion in 2026, underscoring the commercial context for this patented technology.
SciSparc Ltd. reported that it has closed the acquisition of the complete intellectual property portfolio of Xylo Technologies Ltd., including patents, trademarks, know-how, brand names and related registered and unregistered rights. As consideration at closing on January 26, 2026, SciSparc issued Xylo pre-funded warrants to purchase 1,017,391 ordinary shares at an exercise price of $0.001 per share, in lieu of ordinary shares.
The pre-funded warrant is fully paid, exercisable from the issuance date for five years, and includes standard adjustment features, transferability, and protections in the event of corporate actions. It also contains a 9.99% Beneficial Ownership Limitation, which restricts exercises that would cause the holder and its affiliates to own more than that percentage of SciSparc’s outstanding ordinary shares.
L.I.A. Pure Capital Ltd., an Israel-organized company, filed a Schedule 13G reporting a significant passive ownership position in SciSparc Ltd. ordinary shares. It reports beneficial ownership of 435,475 ordinary shares, with sole voting and sole dispositive power over all of these shares.
This holding represents 9.26% of SciSparc’s ordinary shares, based on 4,700,501 ordinary shares issued and outstanding as of the reporting date, a figure the issuer provided to the reporting person. The filing is made on a passive basis, with a certification that the securities were not acquired and are not held for the purpose of changing or influencing control of SciSparc.
SciSparc Ltd. is issuing 766,170 ordinary shares in a registered direct offering at $1.00 per share, for estimated net proceeds of about $0.7 million after offering expenses. Shares outstanding were 3,584,331 as of January 13, 2026 and are expected to be 4,350,501 after the sale.
The company plans to use the cash for working capital, including research and development, general corporate purposes, and potential strategic investments that may differ from its current business focus. Recent developments include a non-binding term sheet for its majority-owned subsidiary NeuroThera to acquire 55% of a quantum computing bio data analytics company, and an agreement for SciSparc to acquire the MUSE endoscopic IP portfolio from Xylo in exchange for shares (or pre-funded warrants) equal to 19.99% of its outstanding equity.
The document highlights significant risks, including potential dilution, an auditor going-concern paragraph, and a Nasdaq notice that the company fell below the $2.5 million stockholders’ equity requirement, creating a risk of delisting if compliance is not restored.
SciSparc Ltd. reported that it entered into a securities purchase agreement for a registered direct offering of 766,170 Ordinary Shares at $1.00 per share. This offering is expected to generate gross proceeds of approximately $766,170, which the company plans to use for working capital and general corporate purposes, as determined by its board of directors.
The shares are being issued under an existing shelf registration statement on Form F-3 via a prospectus supplement filed on January 13, 2026, and the closing of the offering is expected on or about January 14, 2026. An Israeli legal opinion confirms that the Ordinary Shares issued in the offering are validly issued, fully paid and non-assessable.
SciSparc Ltd. reported that on January 8, 2026 it signed an asset purchase agreement with Xylo Technologies Ltd. to acquire Xylo’s complete portfolio of patents, trademarks, know-how, brand names and related intellectual property rights, including unregistered rights. As consideration, SciSparc agreed to issue ordinary shares to Xylo so that, on the closing date, Xylo will hold Issued Shares representing 19.99% of SciSparc’s issued and outstanding share capital, and SciSparc may instead issue pre-funded warrants in whole or in part.
The transaction is expected to close on March 8, 2026, subject to customary closing conditions. SciSparc is obligated to ensure the Issued Shares represent 19.99% at closing and to file a registration statement with the SEC within 30 days after closing to register the resale of the Issued Shares. The company also highlighted a related press release describing the acquired portfolio as a “treasury of patents for the endoscope market – entering multi-billion dollar opportunity.”
SciSparc Ltd. reported that Nasdaq has notified the company it no longer meets the Nasdaq Capital Market’s minimum stockholders’ equity requirement of $2,500,000. In a prior Form 6-K, SciSparc disclosed stockholders’ equity of approximately $(81,000) as of June 30, 2025, triggering the non-compliance notice.
The company has 45 calendar days, until February 26, 2026, to submit a plan to regain compliance, and Nasdaq may grant up to 180 calendar days from the date of the letter to evidence compliance if the plan is accepted. The notice has no immediate effect on SciSparc’s Nasdaq listing, and its ordinary shares will continue to trade under the symbol SPRC during the grace period. SciSparc expects to show compliance as of December 31, 2025, supported by proceeds from the August 2025 conversion of $4.2 million principal plus accrued interest of debentures dated February 25, 2025 and a registered direct offering in November 2025.
SciSparc Ltd. (SPRC) reported that on November 26, 2025 it entered into a binding term sheet to acquire a complete portfolio of patents, trademarks, know-how, and related intellectual property, mainly associated with the MUSE™ system for innovative endoscopic systems and medical cameras, from Xylo Technologies Ltd.
As consideration for these intellectual property assets, SciSparc agreed to issue to Xylo ordinary shares that will represent, as of the closing date, 19.99% of SciSparc’s issued and outstanding share capital. SciSparc may choose, at its sole discretion, to issue pre-funded warrants to purchase ordinary shares instead of some or all of these shares. Closing is subject to customary conditions, including any required shareholder approval and the negotiation and signing of definitive agreements.
SciSparc also announced this planned acquisition in a press release titled “SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems,” and this report is incorporated by reference into several of the company’s existing Form F-3 and Form S-8 registration statements.
SciSparc Ltd. (SPRC) filed a Form 6-K noting that it has furnished a press release dated November 20, 2025. The release announces that Neurothera Labs submitted an Israeli patent application in collaboration with Clearmind Medicine for a novel non-hallucinogenic neuroplastogen treatment for depression. The filing also states that this Form 6-K is incorporated by reference into several of SciSparc’s existing shelf and employee equity registration statements, meaning the information becomes part of those previously filed offerings.
SciSparc Ltd. furnished a Form 6-K that provides its unaudited consolidated interim financial statements as of June 30, 2025, together with management’s discussion and analysis of financial condition and results of operations for the six months ended June 30, 2025.
The filing is incorporated by reference into SciSparc’s existing registration statements on Form F-3 and Form S-8, so these interim financials and related analysis become part of those offering documents from the submission date.